Genotype-Guided Perioperative Drug Selection: Personalized Medicine in the Operating Room

Abstract

Genotype-guided perioperative drug selection represents a transformative advancement in anesthetic and surgical pharmacotherapy, leveraging individual genetic profiles to optimize drug efficacy, minimize adverse drug reactions, and enhance perioperative outcomes. This review synthesizes current scientific evidence, including recent clinical trials and guideline recommendations, to provide an in-depth appraisal of genotype-driven prescribing in the perioperative setting. Emphasis is placed on the implications for anesthetic agents, analgesics, and anticoagulants, with practical insights for integrating pharmacogenomics into clinical workflows for surgical patients.

Introduction

The perioperative period is characterized by complex pharmacologic interventions, with patients exposed to a spectrum of anesthetics, analgesics, and adjunctive medications. Interindividual variability in drug response is a significant contributor to perioperative morbidity and mortality. Advances in pharmacogenomics have paved the way for genotype-guided drug selection, offering the potential to tailor pharmacotherapy to the patient’s genetic makeup. This approach aims to achieve precision medicine, maximizing therapeutic benefit while reducing the risk of adverse drug reactions (ADRs), which remain a leading cause of perioperative complications.

Epidemiology / Disease Burden

Adverse drug reactions are implicated in up to 20% of perioperative complications, with genetic factors accounting for a substantial proportion of these events. The prevalence of actionable pharmacogenetic variants—such as CYP2D6, CYP2C19, SLCO1B1, and VKORC1—varies across populations, with studies reporting carrier rates ranging from 5% to 40% depending on the allele and ethnicity. Notably, the global burden of perioperative morbidity attributable to inappropriate drug selection or dosing is significant, underscoring the clinical and economic imperative for individualized drug regimens.

Pathophysiology

Genetic polymorphisms in drug-metabolizing enzymes, transporters, and target receptors underlie much of the observed variability in perioperative drug response. For example, CYP2D6 polymorphisms influence the metabolism of opioids such as codeine and tramadol, leading to either therapeutic failure or toxicity. Variants in CYP2C9 and VKORC1 affect warfarin sensitivity, increasing the risk for bleeding or thromboembolism. Similarly, mutations in RYR1 and CACNA1S are associated with malignant hyperthermia susceptibility, a life-threatening anesthetic complication. Understanding the mechanistic basis of these genetic influences is pivotal for safe and effective drug selection in surgical patients.

Risk Factors

Risk factors for genotype-related perioperative drug complications include known carrier status for pharmacogenetically relevant alleles, a family history of ADRs or malignant hyperthermia, polypharmacy, advanced age, and comorbid liver or renal dysfunction. The risk is further amplified in populations with high prevalence of certain genetic variants, such as Asian populations with increased CYP2C19 loss-of-function alleles or African ancestry patients with higher frequencies of CYP2D6 ultra-rapid metabolizers.

Clinical Features

Genotype-influenced drug responses manifest as a spectrum of clinical features, from exaggerated pharmacologic effects (e.g., opioid-induced respiratory depression in CYP2D6 ultra-rapid metabolizers) to lack of efficacy (e.g., clopidogrel non-responsiveness in CYP2C19 poor metabolizers). Rare but severe perioperative complications, such as malignant hyperthermia, are strongly linked to specific genetic mutations. Recognition of these features requires heightened clinical vigilance and integration of pharmacogenetic data into perioperative assessment.

Diagnosis

Pharmacogenetic testing is the cornerstone of diagnosing genotype-related drug response variability. Preoperative genotyping, conducted via blood or buccal swab, can identify actionable variants in key genes. In emergent settings, point-of-care genetic assays are increasingly accessible, enabling rapid risk stratification. Diagnosis of perioperative pharmacogenomic syndromes—such as malignant hyperthermia—may also involve muscle contracture testing and family pedigree analysis alongside genetic testing.

Treatment & Management

Genotype-guided perioperative drug selection involves choosing anesthetic and adjunctive agents based on the patient’s genetic profile. For example, patients with CYP2D6 poor metabolizer status may require alternative analgesics to codeine or tramadol, while CYP2C19 poor metabolizers may benefit from direct oral anticoagulants over clopidogrel. Dose adjustments, drug substitutions, and heightened monitoring are integral components of management. Multidisciplinary collaboration among anesthesiologists, surgeons, pharmacists, and geneticists is essential for successful implementation.

Recent Advances / Emerging Therapies

Technological advances have enabled rapid, cost-effective pharmacogenetic testing, with integrated clinical decision support tools now available in many electronic health record systems. Emerging research focuses on polygenic risk scores and whole-exome sequencing to further refine perioperative risk stratification. Recent clinical trials demonstrate improved outcomes with genotype-guided warfarin dosing and opioid prescribing. Novel anesthetic agents with reduced pharmacogenomic liability are under investigation, and machine learning approaches are being harnessed to predict drug responses based on multi-omic data.

Guideline Recommendations

Professional societies, including the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the American Society of Anesthesiologists, now endorse pharmacogenomic testing for select perioperative drugs, particularly in patients with a history of ADRs or those at high risk for pharmacogenomic syndromes. Guidelines recommend preoperative genotyping for VKORC1 and CYP2C9 in patients anticipated to receive warfarin, CYP2D6 for opioid analgesics, and RYR1/CACNA1S in those with suspected malignant hyperthermia susceptibility. Implementation should be supported by institutional protocols and provider education.

Conclusion

Genotype-guided perioperative drug selection heralds a new era of precision medicine in surgical care. By integrating pharmacogenomic data into perioperative workflows, clinicians can enhance drug efficacy, reduce adverse events, and optimize patient outcomes. Continued research, robust clinical implementation, and interdisciplinary collaboration will be pivotal in realizing the full potential of this approach for individualizing perioperative pharmacotherapy.